Low Dose Naltrexone (LDN): A Complete Patient Guide

Low dose naltrexone keeps coming up in patient groups, clinic waiting rooms and late night searches. You see stories about pain easing, better sleep, a little more energy. You also see doubts, because the science is still growing. If you feel caught between hope and caution, you are not alone.

This guide walks you through the essentials in clear English. What LDN is, where it may help, what the research shows, how safe it is and how people in the UK actually get it. I will keep it practical and I will say when the evidence is thin. The aim is simple. Help you have a better conversation with your doctor and help you decide if LDN belongs in your plan.

What is low dose naltrexone (LDN)

Naltrexone is a medicine that blocks opioid receptors. At the standard dose used for alcohol dependence the usual tablet is 50 mg daily. That is an NHS accepted use in the UK and it tells us a lot about basic safety, interactions and what to avoid, like taking opioid painkillers with it [1]. 

Low dose naltrexone uses a fraction of that amount. Most regimens sit somewhere between 0.5 mg and 4.5 mg taken once daily. Researchers first explored these small doses because they seemed to do something different from the standard dose. In lab and early clinical work, low doses appear to nudge immune cells in the brain and spinal cord, calm microglial activation and change inflammatory signalling. That proposed mechanism helps explain why people study LDN in pain and autoimmune conditions, not only in addiction care [7]. 

How is LDN different from standard naltrexone

• Standard dose: 50 mg for alcohol dependence through NHS services, long receptor blockade, clear rules about not mixing with opioids [1]. 
• Low dose: usually up to 4.5 mg, short receptor blockade, explored off label for chronic symptoms that involve pain, fatigue, inflammation [7]. 

Conditions studied with LDN

People read about LDN because it spans several long term conditions. The list below highlights areas with published research. Evidence strength varies by condition.

Fibromyalgia

Small trials from an academic pain lab reported reductions in pain intensity and improved pain thresholds with LDN compared with placebo. Sample sizes were small and the authors called for larger parallel group trials, but the signal is consistent in their work [2]. 

What this means for you

• If standard options have not helped enough, LDN sits on the list of off label choices some UK clinicians consider.
• Response is individual. Some people report better sleep and lower pain, others notice little change.

Multiple sclerosis

UK charities review the MS data and call it mixed. A Milan study suggested LDN was safe and well tolerated, with a reduction in spasticity, but half reported more pain. Trials were short and not designed to show impact on disability or relapse. There is no evidence LDN slows MS progression. This is important to know before you set expectations [4]. 

Crohn’s disease and ulcerative colitis

A double blind trial in adults with moderate to severe Crohn’s disease found higher clinical and endoscopic response with naltrexone compared with placebo over 12 weeks. The study was small, yet it suggested a real effect and supported further trials [3]. 

The broader inflammatory bowel disease picture remains early stage. You will find pilot studies, open label work and a protocol for a larger multicentre trial. If you live with IBD the take home is cautious optimism, not a guaranteed result.

Chronic fatigue syndrome and allied conditions

LDN is discussed in UK ME and CFS communities and some guidance pages summarise patient reports and limited research. They also stress the reality that NHS funding for an unlicensed use may be difficult to secure [6]. 

Addictions and dependency disorders

While standard-dose naltrexone is already licensed in the UK for alcohol dependence, researchers have also explored whether low doses could support recovery from other addictions, including opioid and behavioural addictions such as sex or gambling. Early studies and case reports suggest that LDN’s effect on brain reward pathways and inflammation may help reduce cravings and improve mood stability. However, the evidence base remains very small, and most addiction treatment programmes continue to use the licensed higher-dose regimen. Anyone considering LDN for these uses should do so under medical guidance and as part of a broader recovery plan.

Other off label areas

Neuropathic pain, complex regional pain syndrome, pruritus and long covid symptoms appear in case series and small studies. Mechanism proposals centre on immune modulation through microglia and pattern recognition receptors. The quality of evidence is uneven, so decisions should be personalized.

How effective is LDN

There is no single number to quote across conditions. The best way to think about LDN right now is as a low risk option with modest evidence that seems strongest in fibromyalgia, emerging in IBD and inconsistent in MS.

Highlights from published work

• Fibromyalgia studies from one group show clinically meaningful pain reductions and improved thresholds with LDN compared with placebo, urging larger trials [2]. 
• Crohn’s disease trial reports higher endoscopic response and remission rates with naltrexone than placebo over 12 weeks, again with small numbers [3]. 
• MS charity summaries classify benefit as uncertain. Safety looks acceptable. Disease modification is not proven [4]. 
• Studies suggest LDN may help reduce cravings and improve mood in people with alcohol or opioid dependence.

You may prefer stories to stats. Fair. Patient communities often describe small wins rather than miracles. Less morning stiffness. Fewer pain spikes. Slightly better sleep by week three. Some feel nothing. That spread is normal for an off label option.

Safety and side effects

Most people tolerate LDN well. Common reports include lighter sleep at first, vivid dreams, mild headache or temporary stomach upset. These often settle as the dose is adjusted. A practical way to limit problems is slow titration, which you will see below [5]. 

Important safety notes

• Do not combine LDN with opioid painkillers. Naltrexone blocks opioid receptors and can stop medicines like codeine from working. You also risk withdrawal if opioids are in your system. Speak to your prescriber to plan any switch [1]. 
• If you have liver disease or past abnormal liver tests, mention it. Clinicians may monitor liver function, especially if you have other risk factors.
• If you are pregnant, trying to conceive or breastfeeding, ask your doctor to review current evidence and alternatives.
• Allergic reactions are uncommon, but seek help if you develop a rash, wheeze or swelling.

I think the best test for any new medicine is this simple question. Do the expected benefits, for you, outweigh the nuisance and the small risks. Your answer matters more than any general rule.

How to access LDN in the UK

LDN is an off label use of a licensed medicine. That phrase shapes the path to a prescription.

NHS route

Some NHS clinicians may prescribe naltrexone off label when they judge benefit to outweigh risk, but funding is not guaranteed. Charities explain that off licence use is the prescriber’s direct responsibility and that local policies vary. Many people do not obtain LDN through the NHS, which is frustrating, yet honest to acknowledge [4] [6]. 

Private route

• Private doctors and clinics commonly prescribe LDN after assessing suitability and interactions.
• UK compounding pharmacies supply liquid or capsules at custom strengths.
• Costs vary by clinic and pharmacy. Many patients pay an initial consult fee then a modest monthly medicine cost.

Starting LDN treatment

A careful start makes a big difference. Most people do better with a low starting dose and slow increases.

Typical titration plan

• Begin at 0.5 mg to 1 mg at night.
• Increase by 0.5 mg to 1 mg every 1 to 2 weeks.
• Common target dose is 3 mg to 4.5 mg once daily.
• If sleep becomes too light, some switch to a morning dose or drop back a step.
• Liquid formulations allow small adjustments, which helps sensitive patients 

What to expect in the first few weeks

• Week 1 to 2: you may notice lighter sleep or vivid dreams. Many see this as a sign the dose is active.
• Week 3 to 4: small shifts in pain or energy become clearer, if you are going to respond.
• Weeks 5 to 8: dose adjustments continue. Keep a simple symptom diary, with two or three scores you care about. That helps you and your clinician decide whether to continue.

A quick tip from clinic life. If you change more than one thing at a time, you will not know what helped. Keep it simple.

Integrating LDN into your treatment plan

LDN works best when the rest of your plan pulls in the same direction.

• Review all medicines to avoid clashes with opioids.
• Keep existing disease-modifying or flare-prevention therapy in place unless your specialist plans a change.
• Add one lifestyle action you can keep. Regular movement, sleep timing or pacing your day.
• Consider a pain management course, CBT based support or group physiotherapy if those fit your goals.
• Agree on a checkpoint. Many people use 8 to 12 weeks to review benefit, dose and whether to continue.

No medicine replaces the basics. LDN is no different.

Patient stories

These are composites that reflect common experiences shared by UK patients. They are not proof. They help you picture what “good” and “not so good” can look like.

Ella, 34, fibromyalgia
She started at 0.5 mg. Sleep was odd in week one then settled. By week three, late afternoon pain felt less sharp. At 3 mg she noticed fewer flares after busy days. She still has bad days. Her words, not cured, just less chaos.

Haroon, 51, Crohn’s disease
On stable maintenance therapy but still fatigued. His gastroenterologist would not prescribe LDN. A private prescriber started 1 mg and moved to 4 mg. Bowels did not change much, but his energy improved after six weeks. He kept it because life felt easier.

Mo, 42, MS spasticity
Hoped for better stiffness control. After two months at 4.5 mg he felt no change and had lighter sleep that he disliked. He chose to stop. He said the honest update from the clinic made that decision simple.

Frequently asked questions

How to talk to your doctor about LDN

You can make this easy for your GP or specialist.

• Bring a one page summary of your condition, current medicines and goals.
• Ask for a view on safety first then on likely benefit for your specific case.
• If they are unfamiliar, share a neutral summary or charity resource that explains off label use and evidence. The MS Society and Action for ME pages are useful starting points.
• If NHS prescribing is not possible, ask about reputable private options and how follow up should work.

A good clinician will help you weigh benefit, risk and cost without judgement.

Quick start checklist

• Confirm you are not taking any opioids.
• Agree a slow titration plan and a review date.
• Keep a symptom diary with two or three items you care about.
• Know what side effects to watch for.
• Decide in advance what success looks like for you.

Key points to remember

• Low dose naltrexone is different from standard dose naltrexone for addiction care.
• Evidence is modest and varies by condition. Best signals appear in fibromyalgia and emerging IBD data.
• Safety profile is generally good at low doses, with predictable early sleep effects.
• UK access often runs through private prescribers because LDN is off label.
• A slow, measured start with clear goals helps you decide if it earns a place in your plan.

If you want a next step, write your questions down and book a short appointment with your GP or a reputable private prescriber. Bring this guide. Make the decision together.

References

1. National Health Service. (n.d.). Treatment: Alcohol misuse. NHS. https://www.nhs.uk/conditions/alcohol-misuse/treatment/
2. Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism, 65(2), 529–538. https://doi.org/10.1002/art.37734
3. Smith, J. P., Bingaman, S. I., Ruggiero, F., Mauger, D. T., Mukherjee, A., McGovern, C. O., & Zagon, I. S. (2011). Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: A randomized placebo-controlled trial. Digestive Diseases and Sciences, 56(7), 2088–2097. https://doi.org/10.1007/s10620-011-1653-7
4. MS Society. (n.d.). Low-dose naltrexone (LDN). https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/low-dose-naltrexone-ldn
5. LDN Research Trust. (2024). LDN 2024 dosing information for prescribers. https://ldnresearchtrust.org/sites/default/files/2024-02/Dosing-Guide-2024_0.pdf
6. Action for ME. (n.d.). Low dose naltrexone. https://www.actionforme.org.uk/resource/low-dose-naltrexone/
7. Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2